CAVINTONUM (Cavinton) *.
Ethyl ether of apovinkaminovy acid.
Synonyms: Vinpocetine, Vinpocetine, Vinpocetinum, Inex.
White crystal powder, almost nerastoory in water, is alcohol-soluble.
Cavintonum (Vinpocetine) is to semi-synthetic derivatives of alkaloid of Devincanum which is contained in a plant a periwinkle (Vinica minor L. and Vinca erecta Rgl. et Schmalth); this. dogbane family (Apocynaceae).
Earlier it was established that periwinkle extracts have vasodilating and hypotensive effect, have some sedation. The alkaloid emitted from a periwinkle Vincaminum (methyl ether of vinkaminovy acid) was offered for use (under names 'Devincanum', 'Minorinum' - Devincan, Minorin) as vasodilator. As a result of clinical trials, it was established that Devincanum is especially effective at disturbances of cerebral circulation, and drug Cavintonum which received the international name 'Vinpocetine' is created further.
Cavintonum expands brain vessels, strengthens a blood stream, improves supply of a brain with oxygen and also promotes glucose utilization. Inhibiting phosphodiesterase, drug brings to nakoplennyu in tsAMF fabrics; reduces aggregation of thrombocytes. Only small lowering of the system ABP is observed.
Vasodilating effect of Cavintonum is connected with the direct relaxing impact on unstriated muscles. Drug promotes strengthening of metabolism of noradrenaline and serotonin in brain tissues, reduces patholologically the increased viscosity of blood, promotes deformability of erythrocytes.
Apply at the neurologic and mental disturbances connected with disorders of cerebral circulation (after the had stroke, posttraumatic, atherosclerotic origin); in dysmnesias, dizziness, aphasia, etc.; in hypertensive encephalopathy, vazovegetativny symptoms in a climacteric, etc.
In ophthalmologic practice Cavintonum is appointed at atherosclerotic and angiospastic changes of mesh and vascular covers, degenerative changes of a macula lutea, the secondary glaucoma connected with partial fibrinferments of vessels, etc.
It is effective also in a hearing impairment of vascular or toxic (medicamentous) origin and dizziness of labyrinth origin.
Accept inside in the form of tablets (5 mg) on 1 - 2 tablets 3 times a day. A maintenance dose - 1 tablet 3 times a day. Apply it is long. Improvement is observed usually in 1 - 2 week; course of treatment about 2 months and more.
Intravenously (only by drop infusion) apply in nevrologichesny practice in acute focal ischemic disorders of cerebral circulation, in case of lack of a hemorrhage. Enter 10 - 20 mg (1 - 2 ampoules) into 500 - 1 Ltd companies of ml of isotonic solution of sodium of chloride (drop infusion) in the beginning. If necessary appoint repeated (3 times a day) slow drop infusions, then pass to administration of drug inside.
There are data on use of Cavintonum for prevention of a convulsive syndrome for the children who suffered a brain injury. The drug is administered intravenously by drop infusion at the rate of 8 - 10 mg/kg a day in 5% glucose solution with transition in 2 - 3 weeks to intake on 0, 5 - 1 mg/kg a day.
Usually Cavintonum is well transferred. At intravenous administration the hypotension, tachycardia are possible.
Contraindications: heavy ischemic heart diseases, heavy arrhythmias; do not apply at pregnancy. It is not recommended to appoint drug at the labile ABP and a low vascular tone.
Injection solution is incompatible with heparin. It is impossible to enter solution under skin.
Packagings: tablets on 0, 005 g (5 mg) in packing on 5O of pieces; 0, 5% solution in ampoules on 2 ml (10 mg).
Storage: B list. In the place protected from light.